BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, Ren Y, Liang Z, Zhou P, Zhang Y, Bao Y, Li Y. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer 2020;8:e001748. [PMID: 33323464 DOI: 10.1136/jitc-2020-001748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Möller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, Riechardt S, Simon R, Sauter G, Büscheck F, Höppner W, Matthies C, Doh O, Krech T, Marx AH, Zecha H, Rink M, Steurer S, Clauditz TS. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. Int Urol Nephrol 2021. [PMID: 33797012 DOI: 10.1007/s11255-021-02841-7] [Reference Citation Analysis]
2 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kamakura D, Asano R, Yasunaga M. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals (Basel) 2021;14:1172. [PMID: 34832954 DOI: 10.3390/ph14111172] [Reference Citation Analysis]
4 Liu J, Li Y, Li Q, Liang D, Wang Q, Liu Q. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Res Treat 2021;186:687-97. [PMID: 33634417 DOI: 10.1007/s10549-021-06128-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Reference Citation Analysis]
6 Ye R, Zeng H, Liu Z, Jin K, Liu C, Yan S, Yu Y, You R, Zhang H, Chang Y, Wang Y, Liu L, Zhu Y, Xu J, Xu L, Wang Z. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. Cancer Immunol Immunother 2021. [PMID: 34152439 DOI: 10.1007/s00262-021-02987-4] [Reference Citation Analysis]
7 Lawal G, Xiao Y, Rahnemai-Azar AA, Tsilimigras DI, Kuang M, Bakopoulos A, Pawlik TM. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel) 2021;9:1184. [PMID: 34696292 DOI: 10.3390/vaccines9101184] [Reference Citation Analysis]